Literature DB >> 14512243

The struggle against neuromuscular diseases in France and the emergence of the "partnership model" of patient organisation.

Vololona Rabeharisoa1.   

Abstract

The past few decades have witnessed the increasingly active participation of patient organisations in research activities concerning them. They contribute substantially to the funding of scientific and clinical research. More importantly, certain patient organisations take strategic decisions concerning that research, and contribute to the production of knowledge on their diseases. In France, the AFM (Association Française contre les Myopathies-French Muscular Dystrophy Organisation), is a striking illustration. The paper argues that the model of the AFM's engagement in research-the "partnership model"-is original insofar as it renews the power relations between patients and professionals found in two classic models: the "auxiliary model" and the "emancipatory model". Based on a long-term study of the French Muscular Dystrophy Organisation, this "partnership model" is characterised and its implications discussed in three respects: the possible generalisation of the mode of relations it establishes between patients and professionals; its effects on the steering of research; and its consequences for the dynamics of patient organisations movements.

Entities:  

Mesh:

Year:  2003        PMID: 14512243     DOI: 10.1016/s0277-9536(03)00084-4

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  17 in total

1.  Commentary: a sociologist's view on community genetics.

Authors:  Aviad E Raz
Journal:  J Community Genet       Date:  2010-02-25

2.  Exploring the positions of German and Israeli patient organizations in the bioethical context of end-of-life policies.

Authors:  Aviad Raz; Isabella Jordan; Silke Schicktanz
Journal:  Health Care Anal       Date:  2014-06

Review 3.  The role of brain tumor advocacy groups.

Authors:  Michele Rhee; Paulius Mui; Carl Cadogan; Jonny Imerman; Sarah Lindsell; Lainey Titus Samant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

Review 4.  Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?

Authors:  Devidas Menon; Tania Stafinski; Andrea Dunn; Hilary Short
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

5.  Leveraging Citizen Science and Information Technology for Population Physical Activity Promotion.

Authors:  Abby C King; Sandra J Winter; Jylana L Sheats; Lisa G Rosas; Matthew P Buman; Deborah Salvo; Nicole M Rodriguez; Rebecca A Seguin; Mika Moran; Randi Garber; Bonnie Broderick; Susan G Zieff; Olga Lucia Sarmiento; Silvia A Gonzalez; Ann Banchoff; Juan Rivera Dommarco
Journal:  Transl J Am Coll Sports Med       Date:  2016-05-15

6.  New phosphate langbeinites, K2MTi(PO4)3 (M = Er, Yb or Y), and an alternative description of the langbeinite framework.

Authors:  Stefan T Norberg
Journal:  Acta Crystallogr B       Date:  2002-09-24

7.  Health activism and the logic of connective action. A case study of rare disease patient organisations.

Authors:  Stefania Vicari; Franco Cappai
Journal:  Inf Commun Soc       Date:  2016-03-21

Review 8.  Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review.

Authors:  Andrea Young; Devidas Menon; Jackie Street; Walla Al-Hertani; Tania Stafinski
Journal:  Orphanet J Rare Dis       Date:  2017-12-22       Impact factor: 4.123

9.  Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop.

Authors:  Koichi Mikami; Steve Sturdy
Journal:  Res Involv Engagem       Date:  2017-09-04

10.  Biobanking from the patient perspective.

Authors:  Derick Mitchell; Jan Geissler; Alison Parry-Jones; Hans Keulen; Doris C Schmitt; Rosaria Vavassori; Balwir Matharoo-Ball
Journal:  Res Involv Engagem       Date:  2015-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.